Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.

Study Overview

• Status: Terminated
• Conditions: Thyroid Eye Disease
• Intervention / Treatment: Drug: Kamuvudine-9; Drug: Kamuvudine-9

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Kentucky
    • Lexington, Kentucky, United States, 40506
      • University of Kentucky

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Cohort 1

• Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol

Cohort 2

• Diagnosed with Thyroid Eye Disease (TED).
• Symptomatic TED diagnosed no more than 9 months earlier.
• Clinical Activity Score ≥ 3 (on 7 point scale) for the worse eye.
• Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol.

Exclusion Criteria:

Cohort 1

• Body weight less than 55 kg.
• History of any clinically significant medical disorders the principal investigator considers exclusionary, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.
• Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.
• History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator.
• Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary

Cohort 2

• Body weight less than 55 kg.
• Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.
• History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator.
• Participation in any investigational drug or ocular device study within 30 days prior to the Day 1 Study Visit.
• History or current evidence of a medical condition that may, in the opinion of the investigator, preclude the safe administration of study medication or affect the results of the study.
• Participation in any systemic experimental treatment or any other systemic investigational new drug within 5 half-lives of the active ingredient prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary.
• History of use of teprotumumab (Tepezza), radiotherapy, or orbital surgery.
• History (last 6 weeks) of use of systemic immunosuppressants (e.g. mycophenolate), intravenous immunoglobulin, or plasmapheresis.
• Clinical activity score < 3
• Uncontrolled diabetes or hypertension
• History of mental / psychiatric disorder
• Hepatic dysfunction (Albumin (Alb), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline phosphates levels must be within normal range for eligibility)
• Renal impairment (Urea, Creatinine, and Glomerular Filtration Rate levels must be within normal range)
• Any baseline condition that the principal investigator considers exclusionary.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Healthy Volunteers; Participants receive one dose of 96 mg tablets of K9 based on weight	Drug: Kamuvudine-9; 96 mg tablets taken once; Other Names: K9; Drug: Kamuvudine-9; 96 mg tablets taken twice a day for 24 weeks; Other Names: K9
Experimental: Patients with Thyroid Eye Disease (TED); Participants receive a regimen of 96 mg tablets of K9 twice a day for 24 weeks	Drug: Kamuvudine-9; 96 mg tablets taken once; Other Names: K9; Drug: Kamuvudine-9; 96 mg tablets taken twice a day for 24 weeks; Other Names: K9

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
plasma concentrations of K9	plasma concentrations measured after a single oral dose in healthy adults. For each of these time points 5 ml of blood will be drawn.	Pharmacokinetic samples collected pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, and 24 hours after dosing
Adverse Events	Frequency of participants experiencing ocular or systemic adverse events.	26 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Standardized Patient Evaluation of Eye Dryness (SPEED) symptoms	The SPEED Questionnaire will be used to track progression of dry eye symptoms. The SPEED questionnaire has eight questions. The frequency and severity of symptoms are rated on a numeric scale. Scores range from 0 to 28 with higher scores equating to more symptoms.	Screening (Baseline), and Weeks 4, 14, and 24
Change in Diplopia	Diplopia is assessed by the Bahn-Gorman Scale. The Bahn-Gorman scale is a subjective grading scheme that uses a scale of 0-3 to assess the severity of diplopia. A higher score equates to more severe diplopia.	Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24
Change in Study Visit in Clinical Activity Score (CAS),	Clinical Activity Score (7 point scale) with higher score equating to more symptoms	Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24
Change in proptosis	Hertel exophthalmometry will be used to measure the globe position of the eye by calculating the distance from the lateral orbital rim to the surface of the cornea in millimeters (mm)	Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24
Change in Graves' ophthalmopathy-specific quality-of-life scale (GO-QOL)	The GO-QOL is a self-administered health-related QOL questionnaire specifically designed and validated in patients with TED. It includes 2 subscale GO-QOL scores: (1) visual functioning and (2) appearance-related, with the 2 weighted equally to create an overall score. Both the subscales and overall score are transformed to a scale of 0 to 100, 0 indicating worst health and 100 indicating best health.	Screening (Baseline) and weeks 4, 14, and 24
Change in upper eyelid retraction	upper eyelid retraction will be determined by measuring the margin reflex distance (MRD1) in millimeters. The MRD1 is the measurement in millimetres from the light reflex on the patient's cornea to the level of the centre of the upper eyelid margin, with the patient gazing in the primary position.	Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24
Change in lower eyelid retraction	Lower eyelid retraction is measured by the distance from the inferior limbus to the lower eyelid, or by the margin reflex distance 2 (MRD2). The distance between the corneal light reflex to the central portion of the lower eyelid is measured in millimeters	Screening (Baseline), Day 1 Visit, and weeks 4, 14, and 24
Change in cell-based functional assays	measured by ELISA	Screening (Baseline), Day 1 Visit, and weeks 4,14, and 24

Collaborators and Investigators

• Sponsor: Peter Timoney
• Collaborators: Inflammasome Therapeutics
• Investigators: Principal Investigator: Peter Timoney, University of Kentucky

Study record dates

Study Major Dates

• Study Start (Actual): November 6, 2024
• Primary Completion (Actual): February 23, 2026
• Study Completion (Actual): February 23, 2026

Study Registration Dates

• First Submitted: June 14, 2024
• First Submitted That Met QC Criteria: June 14, 2024
• First Posted (Actual): June 21, 2024

Study Record Updates

• Last Update Posted (Actual): April 1, 2026
• Last Update Submitted That Met QC Criteria: March 27, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Kamuvudine-9; K9
• Additional Relevant MeSH Terms: Endocrine System Diseases; Genetic Diseases, Inborn; Autoimmune Diseases; Immune System Diseases; Eye Diseases; Eye Diseases, Hereditary; Graves Disease; Exophthalmos; Orbital Diseases; Goiter; Hyperthyroidism; Thyroid Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Graves Ophthalmopathy
• Other Study ID Numbers: 94519

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No